Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: Application of comparative molecular field analysis

Journal of Medicinal Chemistry

Volumn 42, Issue 2, 1999, Pages 249-259

  Debnath, Asim Kumar ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3'[[TETRAHYDRO 5ALPHA,6BETA DIHYDROXY 2 OXO 4ALPHA,7BETA BIS(PHENYLMETHYL) 1H 1,3 DIAZEPINE 1,3[2H] DIYL]BIS(METHYLENE)]BIS(N 2 THIAZOLYLBENZAMIDE); 4,7 DIBENZYL 2,3,4,5,6,7 HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS[4 (HYDROXYMETHYL)BENZYL] 2H 1,3 DIAZEPIN 2 ONE; ANTIVIRUS AGENT; MOZENAVIR; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG CONFORMATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME ACTIVE SITE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR INTERACTION; NONHUMAN; PROTEINASE INHIBITION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING; VIRUS INHIBITION;

ANTI-HIV AGENTS; CRYSTALLOGRAPHY, X-RAY; HIV PROTEASE INHIBITORS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 0032946731     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980369n     Document Type: Article

References (57)

1. Debouck, C. The HIV-1 Protease as a Therapeutic Target for AIDS. AIDS Res. Hum. Retroviruses 1992, 8, 153-164.
2. McQuade, T. J.; Tomasselli, A. G.; Liu, L.; Karacostas, V.; Moss, B.; Sawyer, T. K.; Heinrikson, R. L.; Tarpley, W. G. A Synthetic HIV-1 Protease Inhibitor with Antiviral Activity Arrest HIV-like Particle Maturation. Science 1990, 247, 454-456.
3. Meek, T. D.; Lambert, D. M.; Dreyer, G. B.; Carr, T. J.; Tomaszek, T. A., Jr.; Moore, M. L.; Strickler, J. E.; Debouck, C.; Hyland, L. J.; Mathews, T. J.; et al. Inhibition of HIV-1 Protease in Infected T-lymphocytes by Synthetic Peptide Analogues. Nature 1990, 343, 90-92.
4. Winslow, D. L.; Otto, M. J. HIV Protease Inhibitors. AIDS 1995, Suppl. A, S183-S192.
5. Prasad, J. V.; Lunney, E. A.; Para, K. S.; Tummino, P. J.; Ferguson, D.; Hupe, D.; Domagala, J. M.; Erickson, J. W. Nonpeptide Potent HIV-1 Protease Inhibitors. Drug Des. Discov. 1996, 13, 15-28.
6. Deeks, S. G.; Volderding, P. A. HIV-1 Protease Inhibitors. AIDS Clin. Rev. 1997, 145-185.
7. Korant, B. D.; Rizzo, C. J. The HIV Protease and Therapies for AIDS. Adv. Exp. Med. Biol. 1997, 421, 279-284.
8. Deeks, S. G.; Smith, M.; Holodniy, M.; Kahn, J. O. HIV-1 Protease Inhibitors: A Review for Clinicians. J. Am. Med. Assoc. 1997, 277, 145-153.
9. Flexner, C. HIV-Protease Inhibitors. N. Engl. J. Med. 1998, 338, 1281-1292.
10. Kohl, N. E.; Emini, E. A.; Scheif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A.; Scolnik, E. M.; Sigal, I. S. Active Human Immunodeficiency Virus Protease is Required for Viral Infectivity. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4686-4690.
11. Henderson, L. E.; Soweder, R. C.; Copeland, T. D.; Oroszlan, S.; Benveniste, R. E. Gag Precursors of HIV and SIV are Cleaved into Six Proteins Found in the Mature Virions. J. Med. Primatol. 1990, 19, 411-419.
12. Vogt, V. M. Proteolytic Processing and Particle Maturation. Curr. Top. Microbiol. Immunol. 1996, 214, 95-132.
13. Luque, I.; Todd, M. J.; Gomez, J.; Semo, N.; Freire, E. Molecular Basis of Resistance to HTV-1 Protease Inhibition: A Plausible Hypothesis. Biochemistry 1998, 37, 5791-5797.
14. Ala, P. J.; Huston, E. E.; Klabe, R. M.; McCabe, D. D.; Duke, J. L.; Rizzo, C. J.; Korant, B. D.; DeLoskey, R. J.; Lam, P. Y. S.; Hodge, C. N.; Chang, C.-H. Molecular Basis of HIV-1 Drug Resistance: Structural Analysis of Mutant Protease Complexed With Cyclic Urea Inhibitors. Biochemistry 1997, 36, 1573-1580.
15. Jadav, P. K.; Ala, P.; Woerner, F. J.; Chang, C.-H.; Garber, S. S.; Anton, E. D.; Bacheler, L. T. Cyclic Urea Amides: HIV-1 Protease Inhibitors with Low Nanomolar Potency against both Wild-Type and Protease Inhibitor Resistant Mutants of HIV. J. Med. Chem. 1997, 40, 181-191.
16. Ridky, T.; Leis, J. Development of Drug Resistance to HIV-1 Protease Inhibitors. J. Biol. Chem. 1995, 270, 29621-29623.
17. Cho, S. J.; Serrano Gracia, M. L.; Bier, J.;Tropsha, A. Structure-based Alignment and Comparative Molecular Field Analysis of Acetylcholinesterase Inhibitors. J. Med. Chem. 1996, 39, 5064-5071.
18. Boyd, D. B. Successes of Computer-Assisted Molecular Design. In Reviews in Computational Chemistry; Lipkowitz, K. B., Boyd, D. B., Eds.; VCH: New York, 1990; pp 355-371.
19. Cramer, R. D., III; Patterson, D. E.; Bunce, J. D. Comparative Molecular Field Analysis (CoMFA). 1. Effect of Shape on Binding of Steroids to Carrier Proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
20. Kim, K. H. Comparison of Classical and 3D QSAR. In 3D QSAR in Drug Design: Theory Methods and Applications; Kubinyi, H., Ed.; ESCOM: Leiden, 1993; pp 619-642.
21. Debnath, A. K.; Jiang, S.; Strick, N.; Lin, K.; Haberfield, P.; Neurath, A. R. Three-Dimensional Structure-Activity Analysis of a Series of Porphyrin Derivatives with Anti-HIV-1 Activity Targeted to the V3 Loop of the gp120 Envelope Glycoprotein of the Human Immunodeficiency Virus type 1. J. Med. Chem. 1994, 37, 1099-1108.
22. Martin, Y. C.; Lin, C. T.; Wu, J. Application of CoMFA to D1 Dopaminergic Agonists: A Case Study. In 3D QSAR in Drug Design: Theory Methods and Applications; Kubinyi, H., Ed.; ESCOM: Leiden, 1993; pp 643-660.
23. Pajeva, I.; Wiese, M. Molecular Modeling of Phenothiazines and Related Drugs As Multidrug Resistance Modifiers: A Comparative Molecular Field Analysis Study. J. Med. Chem. 1998, 41, 1815-1826.
24. Lieske, S. F.; Yang, B.; Eldefrawi, M. E.; MacKerell, A. D., Jr.; Wright, J. (-)-3-Beta-Substituted Ecgonine Methyl Esters As Inhibitors For Cocaine Binding and Dopamine Uptake. J. Med. Chem. 1998, 41, 864-876.
25. Swaan, P. W.; Szoka, F. C., Jr.; Oie, S. Molecular Modeling of The Intestinal Bile Acid Carrier: A Comparative Molecular Field Analysis Study. J. Comput.-Aided Mol. Des. 1997, 11, 581-588.
26. Moro, S.; van Rhee, A. M.; Sanders, L. H.; Jacobson, K. A. Flavonoid Derivatives As Adenosine Receptor Antagonists: A Comparison of the Hypothetical Receptor Binding Site Based on A Comparative Molecular Field Analysis Model. J. Med. Chem. 1998, 41, 46-52.
27. Schmetzer, S.; Greenidge, P.; Kovar, K. A.; Schulze-Alexandru, M.; Folkers, G. Structure-Activity Relationships of Cannabinoids: A Joint CoMFA and Pseudoreceptor Modelling Study. J. Comput.-Aided Mol. Des. 1997, 11, 278-292.
28. Kaminski, J. J.; Doweyko, A. M. Antiulcer Agents. 6. Analysis of the in vitro Biochemical and in vivo Gastric Antisecretory Activity of substituted imidazol[1,2-a]pyridines and Related Analogues Using Comparative Molecular Field Analysis and Hypothetical Active Site Lattice Methodologies. J. Med. Chem. 1997, 40, 427-436.
29. Appelt, K. Crystal Structures of HIV-1 Protease-Inhibitor Complexes. Perspect. Drug Discov. Des. 1993, 1, 23-48.
30. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F., Jr.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank: A Computer-Based Archival File for Macromolecular Structures. J. Mol. Biol. 1977, 112, 535-542.
31. Wilkerson, W. W.; Akamike, E.; Cheatham, W. W.; Hollis, A. Y.; Collins, R. D.; DeLucca, I.; Lam, P. Y. S.; Ru, Y. HIV Protease Inhibitory Bis-benzamide Cyclic Urea: A Quantitative Structure-Activity Relationship Analysis. J. Med. Chem. 1996, 39, 4299-4312.
32. Wilkerson, W. W.; Dax, S.; Cheatham, W. W. Nonsymmetrically Substituted Cyclic Urea HIV Protease Inhibitors. J. Med. Chem. 1997, 40, 4079-4088.
33. Wei, D. T.; Meadows, J. C.; Kellogg, G. E. Effects of entropy on QSAR equations for HIV-1 protease: 1. Using hydrophobic binding descriptors. 2. Unrestrained complex structure optimization. Med. Chem. Res. 1997, 7, 259-270.
34. Waller, C. L.; Oprea, T. I.; Giolitti, A.; Marshall, G. R. Three-Dimensional QSAR of Human Immunodeficiency Virus (I) Protease Inhibitors. 1. A. CoMFA Study Employing Experimentally-Determined Alignment Rules. J. Med. Chem. 1993, 36, 4152-4160.
35. Oprea, T. I.; Waller, C. L.; Marshall, G. R. Three-Dimensional Quantitative Structure-Activity Relationship of Human Immunodeficiency Virus (I) Protease Inhibitors. 2. Predictive Power Using Limited Exploration of Alternate Binding Modes. J. Med. Chem. 1994, 37, 2206-2215.
36. Oprea, T. I.; Waller, C. L.; Marshall, G. R. 3D-QSAR of Human Immunodeficiency Virus (I) Protease Inhibitors. III. Interpretation of CoMFA Results. Drug Des. Discov. 1994, 12, 29-51.
37. Debnath, A. K. Comparative Molecular Field Analysis (CoMFA) of a Series of Symmetrical Bis-Benzamide Cyclic Urea Derivatives as HIV-1 Protease Inhibitors. J. Chem. Inf. Comput. Sci. 1998, 38, 761-767.
38. Lam, P. Y.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; et al. Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas As HIV Protease Inhibitors. Science 1994, 263, 380-384.
39. Nugiel, D. A.; Reese, K. Synthesis of Novel Cyclic Urea Based HIV-1 Protease Inhibitors. Drug. Des. Discov. 1995, 13, 83-87.
40. Sham, H. L.; Zhao, C.; Stewart, K. D.; Betebenner, D. A.; Lin, S.; Park, C. H.; Kong, X. P.; Rosenbrook, W., Jr.; Herrin, T.; Madigan, D.; Vasavanonda, S.; Lyons, N.; Molla, A.; Saldivar, A.; Marsh, K. C.; McDonald, E.; Wideburg, N. E.; Denissen, J. F.; Robins, T.; Kempf, D. J.; Plattner, J. J.; Norbeck, D. W. A Novel, Picomolar Inhibitor of Human Immunodeficiency Virus Type 1 Protease. J. Med. Chem. 1996, 39, 392-397.
41. Hodge, C. N.; Aldrich, P. E.; Bacheler, L. T.; Chang, C. H.; Eyermann, C. J.; Garber, S.; Grubb, M.; Jackson, D. A.; Jadhav, P. K.; Korant, B.; Lam, P. Y.; Maurin, M. B.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Reid, C.; Sharpe, T. R.; Shum, L.; Winslow, D. L.; Erickson-Viitanen, S. Improved Cyclic Urea Inhibitors of The HIV-1 Protease: Synthesis, Potency, Resistance Profile, Human Pharmacokinetics and X-ray Crystal Structure of DMP 450. Chem. Biol. 1996, 3, 301-314.
42. Nugiel, D. A.; Jacobs, K.; Kaltenbach, R. F.; Worley, T.; Patel, M.; Meyer, D. T.; Jadhav, P. K.; De Lucca, G. V.; Smyser, T. E.; Klabe, R. M.; Bacheler, L. T.; Rayner, M. M.; Seitz, S. P. Preparation and Structure-Activity Relationship of Novel P1/ P1′-Substituted Cyclic Urea-Based Human Immunodeficiency Virus Type-1 Protease Inhibitors. J. Med. Chem. 1996, 39, 2156-2169.
43. Lam, P. Y.; Ru, Y.; Jadhav, P. K.; Aldrich, P. E.; DeLucca, G. V.; Eyermann, C. J.; Chang, C. H.; Emmett, G.; Holler, E. R.; Daneker, W. F.; Li, L.; Confalone, P. N.; McHugh, R. J.; Han, Q.; Li, R.; Markwalder, J. A.; Seitz, S. P.; Sharpe, T. R.; Bacheler, L. T.; Rayner, M. M.; Klabe, R. M.; Shum, L.; Winslow, D. L.; Kornhauser, D. M.; Hodge, C. N.; et al. Cyclic HIV Protease Inhibitors: Synthesis, Conformational Analysis, P2/P2′ Structure-Activity Relationship, and Molecular Recognition of Cyclic Ureas. J. Med. Chem. 1996, 39, 3514-3525.
44. Jadhav, P. K.; Ala, P.; Woerner, F. J.; Chang, C. H.; Garber, S. S.; Anton, E. D.; Bacheler, L. T. Cyclic Urea Amides: HIV-1 Protease Inhibitors With Low Nanomolar Potency Against Both Wild-Type and Protease Inhibitor Resistant Mutants of HIV. J. Med. Chem. 1997, 40, 181-191.
45. Nugiel, D. A.; Jacobs, K.; Cornelius, L.; Chang, C. H.; Jadhav, P. K.; Holler, E. R.; Klabe, R. M.; Bacheler, L. T.; Cordova, B.; Garber, S.; Reid, C.; Logue, K. A.; Gorey-Feret, L. J.; Lam, G. N.; Erickson-Viitanen, S.; Seitz, S. P. Improved P1/P1′ Substituents For Cyclic Urea Based HIV-1 Protease Inhibitors: Synthesis, Structure-Activity Relationship, and X-ray Crystal Structure Analysis. J. Med. Chem. 1997, 40, 1465-1474.
46. SYBYL Molecular Modeling System (Version 6.4) is available from Tripos Associates Inc., 1699 South Hanley Rd, St. Louis, MO 63144.
47. HINT 2.25S is available from eduSoft, LC, P.O. Box 1811, Ashland, VA 23005.
48. CrystalEyes 2-Stereo Eyewear is available from StereoGraphics Corp. 2171 East Francisco Blvd, San Rafel, CA 94901.
49. Weiner, S.; Kollman, P. A.; Nguyen, D. T.; Case, D. A. An All Atom Force Field for Simulations of Proteins and Nucleic Acids. J. Comput. Chem. 1986, 7, 230-252.
50. Gasteiger, J.; Marsili, M. Iterative Partial Equalization of Orbital Electronegativity - A Rapid Access to Atomic Charges. Tetrahedron 1980, 36, 3219-3228.
51. Marsili, M.; Gasteiger, J. Pi-Charge Distributions from Molecular Topology and Pi-Orbital Electronegativity. Croat. Chem. Acta 1980, 53, 601-614.
52. Dewar, M. J. S.; Zoelbisch, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: A New General Purpose Quantum Mechanical Molecular Model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
53. Ala, P. J.; DeLoskey, R. J.; Huston, E. E.; Jadhav, P. K.; Lam, P. Y.; Eyermann, C. J.; Hodge, C. N.; Schadt, M. C.; Lewandowski, F. A.; Weber, P. C.; McCabe, D. D.; Duke, J. L.; Chang, C. H. Molecular Recognition of Cyclic Urea HIV-1 Protease Inhibitors. J. Biol Chem. 1998, 273, 325-12331.
54. Clark, M.; Cramer, R. D., III; Van Opdenbosch, N. Validation of the General Purpose Tripos 5.2 Force Field. J. Comput. Chem. 1989, 10, 982-1012.
55. Wold, S.; Ruhe, A.; Wold, H.; Dunn, W. J. The Covariance Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses. SIAM J. Sci. Stat. Comput. 1994, 5, 735-743.
56. Kellogg, G. E.; Semus, S.; Abraham, D. J. HINT: A New Method of Empirical Hydrophobic Field Calculation for CoMFA. J. Comput.-Aided Mol. Des. 1991, 5, 545-552.
57. Folker, G.; Merz, A.; Rognan, D. CoMFA: Scope and Limitations. In 3D QSAR in Drug Design: Theory, Methods and Applications; Kubinyi, H., Ed.; Escom: Leiden, 1993; pp 583-618.